EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

The trial is a Phase 1/2, open label, uncontrolled trial to investigate the safety and

preliminary efficacy of EIS-12656 alone or in combination with a PARPi or T-DXd in

patients with specified advanced or metastatic solid tumors with homologous recombination

deficient (HRD) mutations.

In the Phase 1 dose escalation phase participants will receive ascending doses of

EIS-12656 to evaluate the safety and tolerability and to determine an effective and safe

dose for the Phase 2 part.

In the Phase 2 dose expansion phase participants will either receive EIS-12656

monotherapy at the recommended Phase 2 dose (RP2D) (Module 1) or EIS-12656 in combination

with a PARPi or T-DXd (Modules 2 and 3). The objective is to evaluate the safety and

tolerability and anti-tumor activity of EIS-12656 alone or in combination.